{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T13:23:57Z","timestamp":1794230637847,"version":"4.9.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.10.004","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:19:48Z","timestamp":1792077588000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults With Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-8766","authenticated-orcid":false,"given":"Ken","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Xinyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Hijikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.10.004_bib1","first-page":"S277","article-title":"13. Older adults: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.10.004_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13340-016-0293-8","article-title":"Glycemic targets for elderly patients with diabetes","volume":"7","author":"Haneda","year":"2016","journal-title":"Diabetol Int"},{"key":"10.1016\/j.eprac.2026.10.004_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620933741","article-title":"An overview of prevalence, determinants and health outcomes of polypharmacy","volume":"11","author":"Khezrian","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.eprac.2026.10.004_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105521","article-title":"Effects of multimorbidity and polypharmacy on physical function in community-dwelling older adults: a 3-year prospective cohort study from the SONIC","volume":"126","author":"Yoshida","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.eprac.2026.10.004_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12877-019-1348-z","article-title":"Disability incidence and functional decline among older adults with major chronic diseases","volume":"19","author":"Fong","year":"2019","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.eprac.2026.10.004_bib6","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/gerona\/glaa057","article-title":"Heterogeneous long-term trajectories of dependency in older adults: the PAQUID cohort, a population-based study over 22 years","volume":"75","author":"Edjolo","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.eprac.2026.10.004_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2003.12.049","article-title":"The presence of frailty in elderly persons with chronic renal insufficiency","volume":"43","author":"Shlipak","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eprac.2026.10.004_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.ajkd.2016.08.034","article-title":"Frailty, kidney function, and polypharmacy: the Atherosclerosis Risk in Communities (ARIC) study","volume":"69","author":"Ballew","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eprac.2026.10.004_bib9","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2337\/dc16-2053","article-title":"Psychosocial care for people with diabetes: a position statement of the American Diabetes Association","volume":"39","author":"Young-Hyman","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.10.004_bib10","series-title":"Cognitive aging: Progress in understanding and opportunities for action","year":"2015"},{"key":"10.1016\/j.eprac.2026.10.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.EJ17-0390","article-title":"Frailty in elderly diabetes patients","volume":"65","author":"Yanase","year":"2018","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2026.10.004_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.10.004_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.10.004_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s13300-025-01711-0","article-title":"Tirzepatide for older adults with type 2 diabetes and without obesity: a post hoc analysis of the SURPASS clinical trials","volume":"16","author":"Rasouli","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.10.004_bib15","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1111\/dom.15680","article-title":"Real-world use of tirzepatide in the treatment of type 2 diabetes in an Arab population","volume":"26","author":"Buckley","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.10.004_bib16","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1111\/dom.16237","article-title":"Short-term outcomes of switching from GLP-1 receptor agonists to tirzepatide in type 2 diabetes: a retrospective, observational study in clinical practice","volume":"27","author":"Matsushiro","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.10.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101708","article-title":"GLP-1-derived therapies and sarcopenia: plea for a specific focus on at-risk special populations","volume":"52","author":"Scheen","year":"2026","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.eprac.2026.10.004_bib18","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1111\/dom.15934","article-title":"Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus","volume":"26","author":"Kelly","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.10.004_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.eprac.2026.10.004_bib22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s13300-024-01561-2","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes: analysis of SURPASS-AP-combo by different subgroups","volume":"15","author":"Bi","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.10.004_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13300-024-01660-0","article-title":"Post hoc analysis of SURPASS-1 to -5: efficacy and safety of tirzepatide in adults with type 2 diabetes are independent of baseline characteristics","volume":"16","author":"De Block","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.10.004_bib24","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1111\/dom.70550","article-title":"Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: a multi-site retrospective study","volume":"28","author":"Minakata","year":"2026","journal-title":"Diabetes Obes Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:24:24Z","timestamp":1794227064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26012863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S1530891X26012863"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.10.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults With Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}